Gefinitib vs vinorelbine-cisplatin as adjuvant treatment in stage II-IIIA NSCLC with EGFR-activating mutation - 101341

Spotlight
Video

Gefinitib vs vinorelbine-cisplatin as adjuvant treatment in stage II-IIIA NSCLC with EGFR-activating mutation

obr has 300 videos Subscribe Here

Loading........
Description: Edward Kim, MD of Levine Cancer Institute discusses the use of gefitinib versus standard chemotherapy for patients with stage II-IIIA non-small cell lung cancer with an EGFR mutation. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Shared By : obr
Posted on : 06/21/17
Added : 1 year ago